Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdaf269 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology Advances, online erschienen am 14.01.2026. Verfasst von Maciej Mrugala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medicine and Neurosurgery, Mayo Clinic Cancer Center, Phoenix, Arizona (M.M.). Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease as part of an alliance between AstraZeneca and Merck Sharp.
Abstract (Originalsprache)
Background
Neurofibromatosis type 1 (NF1) is a multisystem genetic condition. Up to 50% of individuals with NF1 develop plexiform neurofibromas (PN) that can cause pain and significant morbidity, impairing quality of life. As of December 2025, only a limited number of countries have an approved medical treatment for adults with NF1-PN. A systematic literature review (PROSPERO CRD42023463980) was conducted to better understand disease burden and unmet need in this population.
Methods
An evidence prioritization strategy identified studies reporting on NF1-PN populations with ≥50% adults from database searches conducted between 1988 and July 20, 2023. Studies published in the last 15 years were extracted.
Results
Of 3242 identified sources, 57 publications (53 unique studies) were included. The proportion of adults with NF1 who had PN ranged from 11.8% to 84.9% (n = 9 studies). Annual median change in untreated PN volume was −3.7% to +8.3% (n = 5 articles). Pain was the most common PN-related manifestation (32.0%–38.4% of patients; n = 12 articles). Malignant PN transformation occurred in 2.0%–4.1% of patients (n = 5 cohorts); 3 shorter-term studies reported no transformation. Surgery was performed in 69.5% of patients (n = 7 cohorts); post-operative complications occurred in 13.0%–30.0% (n = 3 articles). Analgesia was the most reported pharmacological treatment (37.9% of patients; n = 7 articles). Limited data indicated that PN monitoring and surgery cause substantial resource use. No studies reported on caregiver burden, healthcare costs, or transition from pediatric to adult care.
Conclusions
Adults with NF1-PN experience high disease burden. Data gaps exist for epidemiology, transition of care, caregiver burden, healthcare cost, and resource use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Medicine and Neurosurgery, Mayo Clinic Cancer Center, Phoenix, Arizona (M.M.).
- Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts (A.A.).
- Costello Medical, London (J.J.).
- Merck & Co., Inc, Rahway, New Jersey (X.Y.).
- Department of Dermatology (CERENEF), Henri-Mondor Hospital, APHP, UPEC, Créteil, France.
- INSERM CIC 1430, Créteil, France (P.W.).
ORCID-Profile: Ayo Adeyemi
Förderung
- Alexion, AstraZeneca Rare Disease as part of an alliance between AstraZeneca and Merck Sharp
Zitieren
APA
Mrugala, M., Adeyemi, A., Johns, J., Yang, X., & Wolkenstein, P. (2026). Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdaf269
Vancouver
Mrugala M, Adeyemi A, Johns J, Yang X, Wolkenstein P. Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdaf269
BibTeX
@article{Mrugala2026,
author = {Mrugala, Maciej and Adeyemi, Ayo and Johns, Juliet and Yang, Xiaoqin and Wolkenstein, Pierre},
title = {Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdaf269}
}
EUVIMED